Eyas Raddas is a visionary leader in drug discovery and development, with a distinguished career at Eli Lilly and Company since 2001. With a deep expertise in Pharmacokinetics/Pharmacodynamics (PK/PD), Eyas has revolutionized decision-making processes through advanced data analytics and strategic frameworks. At Chorus, he established the PK/PD function, propelling numerous novel drugs to proof-of-concept stages, setting industry benchmarks.

In 2017, Eyas founded and led the Research Decision Analytics function at Lilly Research Laboratories, focusing on portfolio management, decision consulting, and education. After serving COO and portfolio management roles, he moved to his current role of Portfolio Strategy at Lilly’s Diabetes, Obesity and Complications Therapeutic Area, driving innovation in one of the industry’s leading discovery engines.

Eyas is passionate about fostering an innovation culture and has spearheaded multiple initiatives that have measurably enhanced organizational culture. He is a dedicated mentor, guiding scientists to discover their core motivations and career blocks to achieve rapid and fulfilling growth.

A native of Jordan, Eyas holds a BS in Pharmacy from the University of Jordan, a PhD in Pharmaceutics from the University of Georgia, and an MBA from the MIT Sloan School of Management.

Through The Sweet Spot Leader program, Eyas seeks to pass along his experience and wisdom to those who, like him, are dedicated to leading transformational change to make our world a better place for everyone.